The reaffirmation of an Outperform rating and a $9 price target by a reputable analyst like Hartaj Singh from Oppenheimer is likely to instill confidence among investors and could positively influence Gain Therapeutics' stock price in the short term. Analyst ratings, especially those with a positive outlook, can significantly impact investor sentiment and stock prices.